• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Friday's After-Market Session

    3/22/24 5:33:05 PM ET
    $BGXX
    $MASI
    $MESO
    $NTRB
    Medicinal Chemicals and Botanical Products
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $BGXX alert in real time by email

    Gainers

    • Salarius Pharmaceuticals (NASDAQ:SLRX) shares rose 33.9% to $0.83 during Friday's after-market session. The market value of their outstanding shares is at $3.2 million.
    • Masimo (NASDAQ:MASI) shares rose 12.48% to $151.77. The company's market cap stands at $8.0 billion.
    • Vicarious Surgical (NYSE:RBOT) shares moved upwards by 11.17% to $0.38. The market value of their outstanding shares is at $66.7 million.
    • Universe Pharmaceuticals (NASDAQ:UPC) stock moved upwards by 11.11% to $2.2. The company's market cap stands at $8.0 million.
    • Psyence Biomedical (NASDAQ:PBM) stock increased by 9.09% to $1.2. The company's market cap stands at $16.0 million.
    • Bright Green (NASDAQ:BGXX) shares rose 8.02% to $0.29. The company's market cap stands at $53.2 million.

    Losers

    • NextCure (NASDAQ:NXTC) shares declined by 9.5% to $1.72 during Friday's after-market session. The market value of their outstanding shares is at $47.9 million. As per the news, the Q4 earnings report came out yesterday.
    • Rockwell Medical (NASDAQ:RMTI) shares declined by 7.02% to $1.59. The market value of their outstanding shares is at $46.3 million. The company's, Q4 earnings came out yesterday.
    • Mesoblast (NASDAQ:MESO) shares fell 6.49% to $2.02. The company's market cap stands at $204.9 million.
    • Trevena (NASDAQ:TRVN) stock declined by 6.36% to $0.43. The market value of their outstanding shares is at $7.8 million.
    • Shuttle Pharmaceuticals (NASDAQ:SHPH) shares decreased by 6.03% to $0.42. The company's market cap stands at $6.7 million. As per the news, the Q4 earnings report came out yesterday.
    • Nutriband (NASDAQ:NTRB) stock fell 5.93% to $2.54. The market value of their outstanding shares is at $21.4 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $BGXX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BGXX
    $MASI
    $MESO
    $NTRB

    CompanyDatePrice TargetRatingAnalyst
    Mesoblast Limited
    $MESO
    11/25/2025Hold → Buy
    Jefferies
    Masimo Corporation
    $MASI
    11/17/2025Neutral
    BofA Securities
    NextCure Inc.
    $NXTC
    11/7/2025$18.00Neutral → Buy
    Ladenburg Thalmann
    Mesoblast Limited
    $MESO
    7/18/2025Buy → Hold
    Jefferies
    Nutriband Inc.
    $NTRB
    1/22/2025$13.00Outperform
    Noble Capital Markets
    Masimo Corporation
    $MASI
    12/27/2024$170.00 → $194.00Outperform
    Raymond James
    Mesoblast Limited
    $MESO
    12/23/2024Buy → Hold
    Jefferies
    Rockwell Medical Inc.
    $RMTI
    11/14/2024$5.00Buy
    Rodman & Renshaw
    More analyst ratings

    $BGXX
    $MASI
    $MESO
    $NTRB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Nutriband AI Kinesiology Tapes approved for Distribution and Sale in Costa Rica

    ORLANDO, Fla., March 18, 2026 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) today announced that The Costa Rica Ministry of Health has approved the Company's line of Kinesiology Tapes for import and Sale. Innomedica CCB, the company's exclusive distribution partner for Costa Rica oversaw and financed the regulatory approval process. The Company, partnering with Innomedica plans to begin ramping up marketing efforts for these products and its mosquito repellant patch line following this latest approval. About AVERSA™ Abuse-Deterrent Transdermal Technology Nutriband's AVERSA™ abuse-deterrent transdermal technology incorporates aversive agents into transdermal patches to

    3/18/26 7:00:00 AM ET
    $NTRB
    Industrial Specialties
    Health Care

    Mesoblast to Host R&D Day on April 8, 2026

    NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, will host its inaugural R&D Day on Wednesday, April 8, 2026 in New York City. The event will be webcast live from 8:00am to 11:00am EST and will include presentations from Mesoblast's senior leadership team and from key opinion leaders. The event will include discussions regarding the company's corporate strategy, successful commercialization of its flagship product Ryoncil®, and its robust multi-billion-dollar pipeline opportunities in inflammatory pain and cardiovascular disease. In addition, the company will unveil new technol

    3/17/26 7:19:57 PM ET
    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    E.F. Hutton & Co. Serves as Exclusive Placement Agent on Shuttle Pharmaceuticals' $3.5 Million Public Offering

    NEW YORK, March 12, 2026 (GLOBE NEWSWIRE) -- E.F. Hutton & Co. ("E.F. Hutton"), a leading investment banking and financial advisory firm, today announced that it acted as the exclusive placement agent in connection with a $3.5 million public offering by Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) ("Shuttle Pharmaceuticals" or the "Company"), the owner of Molecule.ai, an artificial intelligence ("AI") driven platform for molecular discovery and early-stage drug development. Shuttle Pharmaceuticals entered into a securities purchase agreement with investors for the issuance and sale of 2,238,800 shares of common stock and pre-funded warrants to purchase 4,761,200 shares of common s

    3/12/26 8:30:00 AM ET
    $SHPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BGXX
    $MASI
    $MESO
    $NTRB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider George Gregory

    3 - MESOBLAST LTD (0001345099) (Issuer)

    3/23/26 8:00:19 PM ET
    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3 filed by new insider Krause Philip R.

    3 - MESOBLAST LTD (0001345099) (Issuer)

    3/18/26 5:44:56 PM ET
    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3 filed by Mesoblast Limited

    3 - MESOBLAST LTD (0001345099) (Issuer)

    3/18/26 9:41:13 AM ET
    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BGXX
    $MASI
    $MESO
    $NTRB
    SEC Filings

    View All

    SEC Form DEF 14A filed by Vicarious Surgical Inc.

    DEF 14A - Vicarious Surgical Inc. (0001812173) (Filer)

    3/23/26 4:30:03 PM ET
    $RBOT
    Industrial Specialties
    Health Care

    SEC Form 25-NSE filed by Vicarious Surgical Inc.

    25-NSE - Vicarious Surgical Inc. (0001812173) (Subject)

    3/23/26 9:03:50 AM ET
    $RBOT
    Industrial Specialties
    Health Care

    SEC Form 6-K filed by Mesoblast Limited

    6-K - MESOBLAST LTD (0001345099) (Filer)

    3/23/26 7:52:13 AM ET
    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BGXX
    $MASI
    $MESO
    $NTRB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Mesoblast upgraded by Jefferies

    Jefferies upgraded Mesoblast from Hold to Buy

    11/25/25 8:34:05 AM ET
    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BofA Securities initiated coverage on Masimo

    BofA Securities initiated coverage of Masimo with a rating of Neutral

    11/17/25 9:40:41 AM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    NextCure upgraded by Ladenburg Thalmann with a new price target

    Ladenburg Thalmann upgraded NextCure from Neutral to Buy and set a new price target of $18.00

    11/7/25 8:06:56 AM ET
    $NXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BGXX
    $MASI
    $MESO
    $NTRB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Hanish Arnold C bought $3,740 worth of shares (5,000 units at $0.75) (SEC Form 4)

    4 - Salarius Pharmaceuticals, Inc. (0001615219) (Issuer)

    11/24/25 5:08:13 PM ET
    $SLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Exec VP Finance, CFO Rosenblum Mark J bought $16,000 worth of shares (20,000 units at $0.80), increasing direct ownership by 11,299% to 20,177 units (SEC Form 4)

    4 - Salarius Pharmaceuticals, Inc. (0001615219) (Issuer)

    11/20/25 4:42:09 PM ET
    $SLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chairman of the Board Brennan Michelle bought $30,560 worth of shares (200 units at $152.80), increasing direct ownership by 3% to 7,318 units (SEC Form 4)

    4 - MASIMO CORP (0000937556) (Issuer)

    8/14/25 4:42:13 PM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $BGXX
    $MASI
    $MESO
    $NTRB
    Financials

    Live finance-specific insights

    View All

    Vicarious Surgical Receives Delisting Notice From NYSE

    Vicarious Surgical Inc. (NYSE:RBOT) (the "Company"), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced that on March 3, 2026, it received a notice (the "Notice") from the New York Stock Exchange (the "NYSE") that the NYSE has commenced the process of delisting the Company's Class A common stock, par value $0.0001 per share (the "Common Stock"). Trading on the Company's Common Stock on the NYSE was suspended after market close on March 3, 2026. The NYSE has determined that the Company has fallen below the continued listing standard, requiring listed companies to maintain an average global market capitalization over a con

    3/4/26 7:00:00 AM ET
    $RBOT
    Industrial Specialties
    Health Care

    Rockwell Medical to Release Fourth Quarter and Full-Year 2025 Results on Thursday, March 26, 2026

    Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that it will release its financial and operational results for the fourth quarter and full-year ended December 31, 2025 on Thursday, March 26, 2026. The Company will issue a press release at 6:00am ET followed by a live webcast at 8:00am ET. WEBCAST DETAILS Date: Thursday, March 26, 2026 Time: 8:00am ET Webcast and Replay: www.RockwellMed.com/Results Speakers: Mark Strobeck, Ph.D. — President and Chief Executive Officer Jesse Neri — SVP, Chief Financial Off

    2/26/26 6:00:00 AM ET
    $RMTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Masimo to be Acquired by Danaher for $180.00 Per Share

    Masimo Corporation (NASDAQ:MASI) ("Masimo"), a leading global medical innovator, today announced that it has entered into a definitive agreement pursuant to which Danaher Corporation (NYSE:DHR) ("Danaher") will acquire Masimo for $180.00 per share in cash, representing a total consideration of $9.9 billion (the "Transaction"). The Transaction has been unanimously approved by both Masimo's Board of Directors and Danaher's Board of Directors. Masimo will become a standalone business unit and brand within Danaher's Diagnostics segment and will operate autonomously while strengthening Danaher's offering in acute care settings. Katie Szyman, Chief Executive Officer of Masimo, stated: "We loo

    2/17/26 8:02:00 AM ET
    $DHR
    $MASI
    Industrial Machinery/Components
    Industrials
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $BGXX
    $MASI
    $MESO
    $NTRB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Mesoblast Limited

    SC 13G/A - MESOBLAST LTD (0001345099) (Subject)

    12/16/24 12:08:07 PM ET
    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Psyence Biomedical Ltd.

    SC 13G - PSYENCE BIOMEDICAL LTD. (0001985062) (Subject)

    12/13/24 9:16:01 AM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Psyence Biomedical Ltd.

    SC 13G/A - PSYENCE BIOMEDICAL LTD. (0001985062) (Subject)

    12/9/24 1:36:43 PM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BGXX
    $MASI
    $MESO
    $NTRB
    Leadership Updates

    Live Leadership Updates

    View All

    Dr. Teresa Montagut Appointed as Clinical Development and Medical Affairs Head at Mesoblast

    NEW YORK, March 11, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today announced the appointment of Teresa Montagut MD, PhD in the newly established position of Head of Clinical Development and Medical Affairs reporting to the Chief Medical Officer Dr. Eric Rose. In this role, Teresa will lead Mesoblast's medical affairs organization, fostering clinical collaborations and spearheading investigator-initiated trials, enhancing clinical and medical communications, and engaging with healthcare professionals. She will play a critical role in unlocking the value of Mesoblast's cell therapy programs i

    3/11/26 7:21:39 PM ET
    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Corporate Update: Psyence BioMed Advances Vertically Integrated Pharmaceutical Platform Following PsyLabs Export Milestone

    NEW YORK, March 11, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence BioMed" or the "Company") today reinforced how its strategic investment in PsyLabs strengthens its control over pharmaceutical-grade manufacturing and commercial supply chain infrastructure – a critical differentiator in the rapidly expanding psychedelic pharmaceutical sector. Through its investment in PsyLabs, Psyence BioMed has secured: A licensed, owned, and debt-free production operation.Source-level ibogaine supply.Natural psilocybin supply.GMP-compliant manufacturing capabilities.Intellectual property protection.Integrated analytical and chemistry laboratory infrastructure.A capital structur

    3/11/26 9:15:00 AM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Psyence BioMed Announces Results of Annual and Special Meeting of Shareholders

    NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence BioMed" or the "Company"), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced the voting results from its Annual and Special Meeting of Shareholders (the "Meeting"), held at 9:00 a.m. Eastern Time on February 12, 2026. Shareholders voted in favour of all matters of business presented at the Meeting, including the election of directors, the appointment of auditors and the approval of share consolidation authority for the board of directors (the "Board"). All director nominees listed in the Company's management informat

    2/17/26 9:15:00 AM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care